MHRA-101338-PIP01-24

Key Facts

Active Substance
Active Substance:
  • elinzanetant
Invented Name
Not yet available
PIP Number MHRA-101338-PIP01-24
Pharmaceutical form(s)
  • All pharmaceutical forms
  • All pharmaceutical forms
Therapeutic area
Therapeutic area:
  • Endocrinology-Gynaecology-Fertility-metabolism
Conditions / Indications
Conditions / Indications:
  • Treatment of vasomotor symptoms caused by endocrine therapy related to breast cancer
Route(s) of administration
Route(s) of administration:
  • All routes of administration.
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):elinzanetant.pdf
Published Date 03/10/2024